Abstract: Sodium-glucose co-transporter 2 inhibitors (SGLT2i), a novel type of oral antihyperglycaemic drugs, have demonstrated favorable cardiorenal protective effects in patients with type 2 diabetes or non-diabetic individuals. They can also improve cardiorenal outcomes in patients with chronic kidney disease. Although clinical trials have expanded the inclusion criteria for estimated glomerular filtration rate (eGFR) to lower levels, patients with eGFR < 20 ml／min／1.73m＾2 are still excluded. Whether the continuation of cardiorenal protective effects of SGLT2i during the maintenance dialysis phase is an area of clinical focus. Additionally, the anti-inflammatory and anti-fibrotic properties of SGLT2i may benefit the preservation of peritoneal function in patients undergoing peritoneal dialysis (PD). Therefore, further exploration of the application of SGLT2i in PD patients is warranted.

Key words: sodium-glucose co-transporter 2 inhibitors, peritoneal dialysis, cardiorenal protection, residual kidney function, peritoneal membrane